Rain Therapeutics Inc. Profile Avatar - Palmy Investing

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …

Biotechnology
US, Newark [HQ]

Resulting Ratios

4 Records · Starting from 2019
Loading...
End of RAIN's Analysis
CIK: 1724979 CUSIP: 75082Q105 ISIN: US75082Q1058 LEI: - UEI: -
Secondary Listings
RAIN has no secondary listings inside our databases.